IP Library Granted Patent US 10,631,931
Granted Patent B2
US 10,631,931 · App. 15/372,141 · Granted Apr 28, 2020

Liquid light guide catheter having biocompatible liquid light guide medium

Inventors: Krishn Khanna (Colorado Springs', CO); Robert Splinter (Colorado Springs, CO)
Assignee: THE SPECTRANETICS CORPORATION
A61B18/24A61B18/20A61B18/245A61L29/02G02B6/032A61B2018/00577A61B2018/206A61B2018/2222A61B2018/2244A61B2018/2261
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,631,931
App. No.
15/372,141
Granted
Apr 28, 2020
Kind
B2
Abstract

A method of delivering light energy to target matter in a mammalian body is described. The method may include inserting at least a portion of a catheter into a patient's vasculature, wherein the catheter comprises an open distal tip, a lumen extending proximally from the open distal tip, and at least one optical fiber within the lumen, wherein the at least one optical fiber has a distal end. The method may include flowing a liquid light guide medium through the open-ended catheter tip, wherein the liquid light guide medium flows beyond the distal end of the at least one optical fiber, wherein the liquid light guide medium comprises a magnesium chloride solution having an ion concentration that is isotonic with blood and tissue. The method may include forming a fluid optical channel with the liquid light guide medium between the catheter and the target matter. Other methods are described.

Claims (20)

1. A method of delivering light energy to target matter in a mammalian body, the method comprising:

inserting a portion of a catheter into a patient's vasculature, wherein the catheter comprises an open distal tip, a lumen extending proximally from the open distal tip and at least one optical fiber within the lumen;

positioning the open distal tip to be directed at the target matter;

providing a liquid light guide medium source fluidly coupled to the catheter lumen, wherein a bubble filter is arranged between the liquid light guide medium source and the catheter lumen, and wherein the liquid light guide medium source comprises a reservoir of a liquid light guide medium comprising magnesium chloride solution;

flowing the liquid light guide medium through the bubble filter to the open distal tip via a pump, wherein the liquid light guide medium flows to a distance extending farther than the distal end of the at least one optical fiber;

forming a fluid optical channel with the liquid light guide medium between the catheter and the target matter, wherein the liquid light guide medium comprises the magnesium chloride solution having an ion concentration that is isotonic with blood and tissue, wherein the magnesium chloride solution has a concentration of magnesium chloride up to 2.3% by weight, and wherein the magnesium chloride solution has an index of refraction that is greater than an index of refraction of the blood; and

activating a laser light source to generate the light energy having a wavelength transmitted through the fluid optical channel to the target matter.

2. The method of claim 1 , wherein the method further comprises ablating at least a portion of the target matter with the light energy.

3. The method of claim 1 , wherein the magnesium chloride solution comprises at least one of an aqueous magnesium chloride solution, a pure magnesium chloride solution, solutions of anhydrous magnesium chloride, and solutions of hydrated magnesium chloride.

4. The method of claim 3 , wherein the magnesium chloride solution comprises magnesium chloride hexahydrate (MgCl 2 .6H 2 O).

5. A method of ablating target matter in a mammalian body, the method comprising:

inserting a portion of a catheter into a patient's vasculature, wherein the catheter comprises an open distal tip, a lumen extending proximally from the open distal tip, and a wall enclosing the lumen, and at least one optical fiber within the lumen;

positioning the open distal tip to be directed at the target matter;

providing a liquid light guide medium source fluidly coupled to the catheter lumen, wherein a bubble filter is arranged between the liquid light guide medium source and the catheter lumen, and wherein the liquid light guide medium source comprises a reservoir of a liquid light guide medium comprising magnesium chloride solution;

flowing the liquid light guide medium through the bubble filter to the open distal tip via a pump, wherein the liquid light guide medium flows to a distance extending farther than the distal end of the at least one optical fiber;

forming a fluid optical channel with the liquid light guide medium between the catheter and the target matter, wherein the liquid light guide medium comprises the magnesium chloride solution having an ion concentration that is isotonic with blood and tissue, wherein the magnesium chloride solution has a concentration of magnesium chloride up to 2.3% by weight, and wherein the magnesium chloride solution has an index of refraction that is greater than an index of refraction of the blood;

activating a laser light source to generate the light energy having a wavelength transmitted through the fluid optical channel to the target matter; and ablating the target matter with the light energy.

6. The method of claim 5 , wherein the magnesium chloride solution comprises at least one of aqueous magnesium chloride solutions, pure magnesium chloride solutions, solutions of anhydrous magnesium chloride, solutions of hydrated magnesium chloride, or combinations thereof.

7. The method of claim 6 , wherein the magnesium chloride solution has an index of refraction between 1.335 and 1.420.

8. The method of claim 6 , wherein the magnesium chloride solution comprises magnesium chloride hexahydrate (MgCl 2 .6H 2 O).

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2018
From: KHANNA, KRISHN; SPLINTER, ROBERT
To: THE SPECTRANETICS CORPORATION
Reel/Frame 045723/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0066 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0142 →
SECURITY INTEREST (TERM) Recorded Jun 13, 2017
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 042782/0958 →
SECURITY INTEREST (REVOLVER) Recorded Jun 13, 2017
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 042787/0001 →
Continuity (2)
Continuation 11923488 · Oct 24, 2007
Related Publication 20170086924A1 · Mar 30, 2017